Legal & General Group
KRON

Legal & General Group’s Kronos Bio KRON Stock Holding History

Legal & General Group’s Portfolio KRON Stock Details KRON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-3,512
Closed -$5.14K – 3466
2023
Q1 		$5.14K Hold
3,512
– – ﹤0.01% 3299
2022
Q4 		$5.71K Hold
3,512
– – ﹤0.01% 3335
2022
Q3 		$12K Buy
3,512
+415
+13% +$1.87K ﹤0.01% 3307
2022
Q2 		$11K Sell
3,097
-4,904
-61% -$22.2K ﹤0.01% 3361
2022
Q1 		$58K Hold
8,001
– – ﹤0.01% 2976
2021
Q4 		$109K Hold
8,001
– – ﹤0.01% 2892
2021
Q3 		$167K Buy
8,001
+3,323
+71% +$71.4K ﹤0.01% 2736
2021
Q2 		$112K Buy
4,678
+3,184
+213% +$80.6K ﹤0.01% 2696
2021
Q1 		$44K Sell
1,494
-72
-5% -$2.11K ﹤0.01% 2852
2020
Q4 		$47K Buy
+1,566
New +$49.1K ﹤0.01% 2820

Other funds holding KRON

OFM
Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VVA
Vida Ventures Advisors Boston, Massachusetts $29.4M AUM 93.58% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
PCIG
Partners Capital Investment Group Boston, Massachusetts $2.65B AUM 16.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NI
Nextech Invest Zurich, Switzerland $1.42B AUM 304.47% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Legal & General Group's KRON Position: Q2 2023 in Review

Legal & General Group sold out of Kronos Bio (KRON) in Q2 2023, closing a stake of 3,512 shares — an estimated $5.14K sold.

Legal & General Group first reported a position in KRON in Q4 2020 and held it in 10 quarters. The position peaked at $167K in Q3 2021. 80 funds tracked by Wall St. Rank hold KRON as of Q2 2023.

  • Legal & General Group reported no remaining Kronos Bio position as of Q2 2023 after selling out during the quarter.
  • Legal & General Group sold 3,512 Kronos Bio shares in Q2 2023, an estimated $5.14K.
  • Legal & General Group first reported a position in Kronos Bio in Q4 2020 and held it in 10 quarters.
  • Legal & General Group's Kronos Bio position peaked at $167K in Q3 2021.
  • 80 funds tracked by Wall St. Rank held Kronos Bio as of Q2 2023.

Based on Legal & General Group's 13F filing for Q2 2023, filed 14 Aug 2023.